Lineage Cell Therapeutics (LCTX) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pyxis Oncology (PYXS) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, losing 21.2% versus a loss of 45.2%. Over five years, LCTX leads with a -59.7% price change compared with -82.9% for PYXS. Pyxis Oncology is the larger company by market cap ($240.1 million vs $239.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LCTX | PYXS |
|---|---|---|
| Share price | $0.9476 | $2.01 |
| Market cap | $239.66M | $240.11M |
| 1-day change | +1.03% | -0.50% |
| YTD return | -43.26% | +74.78% |
| 1-year return | -45.23% | -21.18% |
| 5-year return | -59.68% | -82.92% |
| EPS (TTM) | $-0.19 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.09 | $5.55 |
| 52-week low | $0.88 | $1.03 |
| Distance from 52-week high | -54.66% | -63.78% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +480.41% | +331.34% |
| Average volume | 1.15M | 1.26M |
| Shares outstanding | 252.91M | 119.46M |
| Employees | 72 | 56 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYXS has outperformed LCTX by 24.0 percentage points over the past year.
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Healthcare · Biotechnology · 72 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Healthcare · Biotechnology · 56 employees
LCTX vs PYXS FAQ
Which is bigger, Lineage Cell Therapeutics or Pyxis Oncology?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $240.11M compared with $239.66M for Lineage Cell Therapeutics (LCTX).
Which stock has performed better over the past year, LCTX or PYXS?
PYXS returned -21.18% over the past 12 months, compared with -45.23% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are Lineage Cell Therapeutics and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.